{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:16:03Z","timestamp":1790345763758,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82104406"],"award-info":[{"award-number":["82104406"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82274087"],"award-info":[{"award-number":["82274087"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2024Y9512, 2025Y0028"],"award-info":[{"award-number":["2024Y9512, 2025Y0028"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fujian University of Traditional Chinese Medicine Foundation","award":["X2025001"],"award-info":[{"award-number":["X2025001"]}]},{"name":"Fujian Provincial Health Commission science and technology plan project","award":["2023ZQNZD017"],"award-info":[{"award-number":["2023ZQNZD017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Proteolysis-targeting chimeras (PROTACs) have emerged as a promising cancer therapeutic approach by targeting protein degradation to address undruggable targets and drug resistance associated with conventional therapies, yet their clinical translation is hindered by poor solubility and non-specific toxicity. Additionally, tumor heterogeneity and biological complexity frequently limit the efficacy of monotherapies, necessitating the development of multifunctional delivery systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We engineered a dual microenvironment-responsive albumin to integrate conditional PROTAC activation with metabolic starvation and ferroptosis for synergistic antitumor efficacy within a unified therapeutic cascade. Ferrocene (Fc)-modified human serum albumin (HSA) via coupling chemistry was electrostatically complexed with glucose oxidase (GOD) and co-assembled with an azobenzene (AZO)-caged ARV-771 prodrug to yield HSA-Fc-GOD@ARV-771(AZO) nanoparticles that exhibited pH-triggered disassembly in acidic tumor environments. the released GOD consumes glucose and oxygen to generate hydrogen peroxide while inducing metabolic starvation and exacerbating hypoxia. The intensified hypoxia triggers nitroreductase to cleave the prodrug linker and release the active ARV-771, which subsequently degrades bromodomain containing protein 4. This degradation directly suppresses tumor cell proliferation and downregulates glutathione peroxidase 4 expression to sensitize cancer cells to oxidative damage. Concurrently, the ferrocene component converts the generated hydrogen peroxide into hydroxyl radicals via the Fenton reaction to amplify lipid peroxidation and ferroptotic cell death. The nanoplatform suppressed lung cancer cell viability to 10.8% in vitro and achieved 94.3% tumor growth inhibition in xenograft models without observable systemic toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrates a precision therapeutic paradigm. It exploits tumor microenvironment characteristics to couple conditional drug activation with starvation and ferroptosis. This strategy offers a translatable framework for next generation\u2019s cancer treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12951-026-04266-9","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:55:34Z","timestamp":1773057334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dual tumor microenvironment-responsive albumin nanoplatform integrates conditional PROTAC activation with starvation and ferroptosis for synergistic cancer therapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Lingting","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yourui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruocheng","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfei","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"4266_CR1","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","volume":"20","author":"A Leiter","year":"2023","unstructured":"Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat reviews Clin Oncol. 2023;20:624\u201339.","journal-title":"Nat reviews Clin Oncol"},{"key":"4266_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s12951-023-02099-4","volume":"21","author":"Z Chen","year":"2023","unstructured":"Chen Z, Wei X, Zheng Y, Zhang Z, Gu W, Liao W, Zhang H, Wang X, Liu J, Li H. Targeted co-delivery of curcumin and erlotinib by MoS2 nanosheets for the combination of synergetic chemotherapy and photothermal therapy of lung cancer. J Nanobiotechnol. 2023;21:333.","journal-title":"J Nanobiotechnol"},{"key":"4266_CR3","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/cncr.35128","volume":"130","author":"TB Kratzer","year":"2024","unstructured":"Kratzer TB, Bandi P, Freedman ND, Smith RA, Travis WD, Jemal A, Siegel RL. Lung cancer statistics, 2023. Cancer. 2024;130:1330\u201348.","journal-title":"Cancer"},{"key":"4266_CR4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1200\/JCO.22.01503","volume":"41","author":"JR Brahmer","year":"2023","unstructured":"Brahmer JR, Lee J-S, Ciuleanu T-E, Bernabe Caro R, Nishio M, Urban L, Audigier-Valette C, Lupinacci L, Sangha R, Pluzanski A. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non\u2013small-cell lung cancer in CheckMate 227. J Clin Oncol. 2023;41:1200\u201312.","journal-title":"J Clin Oncol"},{"key":"4266_CR5","doi-asserted-by":"publisher","first-page":"2308977","DOI":"10.1002\/adma.202308977","volume":"36","author":"X Zheng","year":"2024","unstructured":"Zheng X, Song X, Zhu G, Pan D, Li H, Hu J, Xiao K, Gong Q, Gu Z, Luo K. Nanomedicine combats drug resistance in lung cancer. Adv Mater. 2024;36:2308977.","journal-title":"Adv Mater"},{"key":"4266_CR6","doi-asserted-by":"publisher","first-page":"100904","DOI":"10.1016\/j.drup.2022.100904","volume":"66","author":"J Li","year":"2023","unstructured":"Li J, Zhu L, Kwok HF. Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment. Drug Resist Updates. 2023;66:100904.","journal-title":"Drug Resist Updates"},{"key":"4266_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s42255-023-00963-z","volume":"6","author":"M Demicco","year":"2024","unstructured":"Demicco M, Liu X-Z, Leithner K, Fendt S-M. Metabolic heterogeneity in cancer. Nat metabolism. 2024;6:18\u201338.","journal-title":"Nat metabolism"},{"key":"4266_CR8","doi-asserted-by":"publisher","first-page":"e202500186","DOI":"10.1002\/cnma.202500186","volume":"11","author":"B Deepika","year":"2025","unstructured":"Deepika B, Janani G, Mercy DJ, Udayakumar S, Raghavan V, Isaac JB, Shurfa M, Girigoswami A, Girigoswami K. Assessing the Anticancer Potential of Cerium Oxide Nanoparticles with Doxorubicin in a Polymeric Nanomatrix: Histopathological and Antiangiogenic Insights. ChemNanoMat. 2025;11:e202500186.","journal-title":"ChemNanoMat"},{"key":"4266_CR9","first-page":"72","volume":"3","author":"Y Liu","year":"2024","unstructured":"Liu Y, Liang J, Zhu R, Yang Y, Wang Y, Wei W, Li H, Chen L. Application of PROTACs in target identification and target validation. Acta materia Med. 2024;3:72.","journal-title":"Acta materia Med"},{"key":"4266_CR10","doi-asserted-by":"publisher","first-page":"116725","DOI":"10.1016\/j.ejmech.2024.116725","volume":"276","author":"S Yan","year":"2024","unstructured":"Yan S, Zhang G, Luo W, Xu M, Peng R, Du Z, Liu Y, Bai Z, Xiao X, Qin S. PROTAC technology: From drug development to probe technology for target deconvolution. Eur J Med Chem. 2024;276:116725.","journal-title":"Eur J Med Chem"},{"key":"4266_CR11","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1016\/j.apsb.2024.04.007","volume":"14","author":"Y Dong","year":"2024","unstructured":"Dong Y, Ma T, Xu T, Feng Z, Li Y, Song L, Yao X, Ashby CR Jr, Hao G-F. Characteristic roadmap of linker governs the rational design of PROTACs. Acta Pharm Sinica B. 2024;14:4266\u201395.","journal-title":"Acta Pharm Sinica B"},{"key":"4266_CR12","doi-asserted-by":"crossref","unstructured":"Raina K, Lu J, Qian Y, Altieri M, Gordon D, Rossi AMK, Wang J, Chen X, Dong H, Siu K. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proceedings of the National Academy of Sciences 2016, 113:7124\u20137129.","DOI":"10.1073\/pnas.1521738113"},{"key":"4266_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/leu.2017.207","volume":"32","author":"B Sun","year":"2018","unstructured":"Sun B, Fiskus W, Qian Y, Rajapakshe K, Raina K, Coleman K, Crew A, Shen A, Saenz D, Mill C. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Leukemia. 2018;32:343\u201352.","journal-title":"Leukemia"},{"key":"4266_CR14","doi-asserted-by":"publisher","first-page":"14155","DOI":"10.1021\/jacs.3c05159","volume":"145","author":"M Chang","year":"2023","unstructured":"Chang M, Gao F, Pontigon D, Gnawali G, Xu H, Wang W. Bioorthogonal PROTAC prodrugs enabled by on-target activation. J Am Chem Soc. 2023;145:14155\u201363.","journal-title":"J Am Chem Soc"},{"key":"4266_CR15","doi-asserted-by":"publisher","first-page":"16642","DOI":"10.1021\/jacs.3c04109","volume":"145","author":"W Wang","year":"2023","unstructured":"Wang W, Zhu C, Zhang B, Feng Y, Zhang Y, Li J. Self-assembled nano-PROTAC enables near-infrared photodynamic proteolysis for cancer therapy. J Am Chem Soc. 2023;145:16642\u20139.","journal-title":"J Am Chem Soc"},{"key":"4266_CR16","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1021\/acs.jmedchem.5c00468","volume":"68","author":"Y Gao","year":"2025","unstructured":"Gao Y, Ni D, Li Y, Zheng J, Zhang K, Xiao Y, Tang X, Li L, Wang X, Wei Y. GLUTs-Facilitated Targeting BRD4 Degradation in Breast Cancer through Carbohydrate-Conjugated PROTACs. J Med Chem. 2025;68:17046\u201364.","journal-title":"J Med Chem"},{"key":"4266_CR17","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jconrel.2020.11.032","volume":"330","author":"JJ Chen","year":"2021","unstructured":"Chen JJ, Qiu M, Ma FH, Yang L, Glass Z, Xu QB. Enhanced protein degradation by intracellular delivery of pre-fused PROTACs using lipid-like nanoparticles. J Controlled Release. 2021;330:1244\u20139.","journal-title":"J Controlled Release"},{"key":"4266_CR18","doi-asserted-by":"publisher","first-page":"2207439","DOI":"10.1002\/advs.202207439","volume":"10","author":"HJ Liu","year":"2023","unstructured":"Liu HJ, Chen W, Wu G, Zhou J, Liu C, Tang Z, Huang X, Gao J, Xiao Y, Kong N. Glutathione-scavenging nanoparticle\u2010mediated PROTACs delivery for targeted protein degradation and amplified antitumor effects. Adv Sci. 2023;10:2207439.","journal-title":"Adv Sci"},{"key":"4266_CR19","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1021\/acs.molpharmaceut.1c00046","volume":"18","author":"A Spada","year":"2021","unstructured":"Spada A, Emami J, Tuszynski JA, Lavasanifar A. The uniqueness of albumin as a carrier in nanodrug delivery. Mol Pharm. 2021;18:1862\u201394.","journal-title":"Mol Pharm"},{"key":"4266_CR20","doi-asserted-by":"publisher","first-page":"13677","DOI":"10.1021\/jacs.5c01274","volume":"147","author":"M Kolokolov","year":"2025","unstructured":"Kolokolov M, Sannikova N, Dementev S, Podarov R, Zhdanova K, Bragina N, Chubarov A, Fedin M, Krumkacheva O. Enhanced Binding Site Identification in Protein-Ligand Complexes with a Combined Blind Docking and Dipolar Electron Paramagnetic Resonance Approach. J Am Chem Soc. 2025;147:13677\u201387.","journal-title":"J Am Chem Soc"},{"key":"4266_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, Sun Y, Zeng F, Chen X, Deng G. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct Target therapy. 2024;9:55.","journal-title":"Signal Transduct Target therapy"},{"key":"4266_CR22","first-page":"100939","volume":"19","author":"X Wang","year":"2024","unstructured":"Wang X, Ren X, Lin X, Li Q, Zhang Y, Deng J, Chen B, Ru G, Luo Y, Lin N. Recent progress of ferroptosis in cancers and drug discovery. Asian J Pharm Sci. 2024;19:100939.","journal-title":"Asian J Pharm Sci"},{"key":"4266_CR23","doi-asserted-by":"publisher","first-page":"102999","DOI":"10.1016\/j.redox.2023.102999","volume":"69","author":"C Xia","year":"2024","unstructured":"Xia C, Xing X, Zhang W, Wang Y, Jin X, Tian M, Ba X, Hao F. Cysteine and homocysteine can be exploited by GPX4 in ferroptosis inhibition independent of GSH synthesis. Redox Biol. 2024;69:102999.","journal-title":"Redox Biol"},{"key":"4266_CR24","doi-asserted-by":"publisher","first-page":"910292","DOI":"10.3389\/fphar.2022.910292","volume":"13","author":"F-J Li","year":"2022","unstructured":"Li F-J, Long H-Z, Zhou Z-W, Luo H-Y, Xu S-G, Gao L-C. System Xc\u2013\/GSH\/GPX4 axis: An important antioxidant system for the ferroptosis in drug-resistant solid tumor therapy. Front Pharmacol. 2022;13:910292.","journal-title":"Front Pharmacol"},{"key":"4266_CR25","doi-asserted-by":"publisher","first-page":"2215022","DOI":"10.1002\/adfm.202215022","volume":"33","author":"X Dai","year":"2023","unstructured":"Dai X, Zhu Y, Su M, Chen J, Shen S, Xu CF, Yang X. Rigid shell decorated nanodevice with Fe\/H2O2 supply and glutathione depletion capabilities for potentiated ferroptosis and synergized immunotherapy. Adv Funct Mater. 2023;33:2215022.","journal-title":"Adv Funct Mater"},{"key":"4266_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.bioactmat.2022.09.025","volume":"22","author":"Y Wang","year":"2023","unstructured":"Wang Y, Wang D, Zhang Y, Xu H, Shen L, Cheng J, Xu X, Tan H, Chen X, Li J. Tumor microenvironment-adaptive nanoplatform synergistically enhances cascaded chemodynamic therapy. Bioactive Mater. 2023;22:239\u201353.","journal-title":"Bioactive Mater"},{"key":"4266_CR27","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1021\/acsnano.4c15932","volume":"19","author":"Q Li","year":"2024","unstructured":"Li Q, Wu Z, Chen S, Liang Y, Zhu K, Su N, Liu T, Zhao B. Enhancing ferroptosis-mediated radiosensitization via synergistic disulfidptosis induction. ACS Nano. 2024;19:1757\u201370.","journal-title":"ACS Nano"},{"key":"4266_CR28","doi-asserted-by":"publisher","first-page":"121643","DOI":"10.1016\/j.carbpol.2023.121643","volume":"326","author":"K Chen","year":"2024","unstructured":"Chen K, Gu L, Zhang Q, Luo Q, Guo S, Wang B, Gong Q, Luo K. Injectable alginate hydrogel promotes antitumor immunity through glucose oxidase and Fe3+ amplified RSL3-induced ferroptosis. Carbohydr Polym. 2024;326:121643.","journal-title":"Carbohydr Polym"},{"key":"4266_CR29","doi-asserted-by":"crossref","unstructured":"Musaie K, Abbaszadeh S, Marais K, Nosrati-Siahmazgi V, Rezaei S, Xiao B, Dua K, Santos HA, Shahbazi MA. H2O2\u2010generating advanced nanomaterials for cancer treatment. Adv Funct Mater. 2025;35:2425866.","DOI":"10.1002\/adfm.202425866"},{"key":"4266_CR30","doi-asserted-by":"publisher","first-page":"103066","DOI":"10.1016\/j.redox.2024.103066","volume":"70","author":"H Zhang","year":"2024","unstructured":"Zhang H, Pan J, Huang S, Chen X, Chang ACY, Wang C, Zhang J, Zhang H. Hydrogen sulfide protects cardiomyocytes from doxorubicin-induced ferroptosis through the SLC7A11\/GSH\/GPx4 pathway by Keap1 S-sulfhydration and Nrf2 activation. Redox Biol. 2024;70:103066.","journal-title":"Redox Biol"},{"key":"4266_CR31","first-page":"6","volume":"18","author":"B Deepika","year":"2023","unstructured":"Deepika B, Agnishwar G, Koyeli G. Antioxidant and anticancer activity of nano lycopene. Res J Biotechnol. 2023;18:6.","journal-title":"Res J Biotechnol"},{"key":"4266_CR32","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1158\/0008-5472.CAN-23-1749","volume":"84","author":"X Zhu","year":"2024","unstructured":"Zhu X, Fu Z, Dutchak K, Arabzadeh A, Milette S, Steinberger J, Morin G, Monast A, Pilon V, Kong T. Cotargeting CDK4\/6 and BRD4 promotes senescence and ferroptosis sensitivity in cancer. Cancer Res. 2024;84:1333\u201351.","journal-title":"Cancer Res"},{"key":"4266_CR33","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(23)00112-2","volume":"24","author":"AM Sonabend","year":"2023","unstructured":"Sonabend AM, Gould A, Amidei C, Ward R, Schmidt KA, Zhang DY, Gomez C, Bebawy JF, Liu BP, Bouchoux G. Repeated blood\u2013brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. Lancet Oncol. 2023;24:509\u201322.","journal-title":"Lancet Oncol"},{"key":"4266_CR34","doi-asserted-by":"crossref","unstructured":"Deng Y, Wang D, Zhao WH, Qiu GH, Zhu XQ, Wang Q, Qin T, Tang JL, Jiang JH, Lin NJ et al. A multifunctional nanocatalytic metal-organic framework as a ferroptosis amplifier for mild hyperthermia photothermal therapy. Research 2024;7:0397.","DOI":"10.34133\/research.0397"},{"key":"4266_CR35","doi-asserted-by":"publisher","first-page":"23198","DOI":"10.1002\/anie.202008732","volume":"59","author":"S Zhou","year":"2020","unstructured":"Zhou S, Hu X, Xia R, Liu S, Pei Q, Chen G, Xie Z, Jing X. A paclitaxel prodrug activatable by irradiation in a hypoxic microenvironment. Angew Chem Int Ed. 2020;59:23198\u2013205.","journal-title":"Angew Chem Int Ed"},{"key":"4266_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jconrel.2016.11.006","volume":"263","author":"Q Chen","year":"2017","unstructured":"Chen Q, Chen J, Liang C, Feng L, Dong Z, Song X, Song G, Liu Z. Drug-induced co-assembly of albumin\/catalase as smart nano-theranostics for deep intra-tumoral penetration, hypoxia relieve, and synergistic combination therapy. J Controlled Release. 2017;263:79\u201389.","journal-title":"J Controlled Release"},{"key":"4266_CR37","doi-asserted-by":"publisher","first-page":"113467","DOI":"10.1016\/j.inoche.2024.113467","volume":"170","author":"HR Ahmed","year":"2024","unstructured":"Ahmed HR, Kayani KF. A comparative review of Fenton-like processes and advanced oxidation processes for Methylene Blue degradation. Inorg Chem Commun. 2024;170:113467.","journal-title":"Inorg Chem Commun"},{"key":"4266_CR38","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1021\/acs.nanolett.3c05039","volume":"24","author":"J Tang","year":"2024","unstructured":"Tang J, Zhu J, Xie H, Song L, Xu G, Li W, Cai L, Han XX. Mitochondria-specific molecular crosstalk between ferroptosis and apoptosis revealed by in situ Raman spectroscopy. Nano Lett. 2024;24:2384\u201391.","journal-title":"Nano Lett"},{"key":"4266_CR39","doi-asserted-by":"publisher","first-page":"2101926","DOI":"10.1002\/adhm.202101926","volume":"11","author":"W Feng","year":"2022","unstructured":"Feng W, Shi W, Liu S, Liu H, Liu Y, Ge P, Zhang H. Fe (III)-shikonin supramolecular nanomedicine for combined therapy of tumor via ferroptosis and necroptosis. Adv Healthc Mater. 2022;11:2101926.","journal-title":"Adv Healthc Mater"},{"key":"4266_CR40","doi-asserted-by":"crossref","unstructured":"Qu N, Song K, Ji Y, Liu M, Chen L, Lee RJ, Teng L. Albumin nanoparticle-based drug delivery systems. Int J Nanomed 2024:6945\u201380.","DOI":"10.2147\/IJN.S467876"},{"key":"4266_CR41","doi-asserted-by":"publisher","first-page":"2307955","DOI":"10.1002\/smll.202307955","volume":"20","author":"A Kumar","year":"2024","unstructured":"Kumar A, Goudar VS, Nahak BK, Tsai PH, Lin HW, Tseng FG. [Ru (dpp) 3] Cl2-embedded oxygen nano polymeric sensors: a promising tool for monitoring intracellular and intratumoral oxygen gradients with high quantum yield and long lifetime. Small. 2024;20:2307955.","journal-title":"Small"},{"key":"4266_CR42","doi-asserted-by":"publisher","first-page":"6863","DOI":"10.1021\/acs.analchem.2c05699","volume":"95","author":"H Guo","year":"2023","unstructured":"Guo H, Yang K, Fan X, Chen M, Ke G, Ren T-B, Yuan L, Zhang X-B. Designing a brightness-restored rhodamine derivative by the ortho-compensation effect for assessing drug-induced acute kidney injury. Anal Chem. 2023;95:6863\u201370.","journal-title":"Anal Chem"},{"key":"4266_CR43","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.freeradbiomed.2024.06.007","volume":"222","author":"H Wang","year":"2024","unstructured":"Wang H, Mao W, Zhang Y, Feng W, Bai B, Ji B, Chen J, Cheng B, Yan F. NOX1 triggers ferroptosis and ferritinophagy, contributes to Parkinson\u2019s disease. Free Radic Biol Med. 2024;222:331\u201343.","journal-title":"Free Radic Biol Med"},{"key":"4266_CR44","doi-asserted-by":"publisher","first-page":"123092","DOI":"10.1016\/j.biomaterials.2025.123092","volume":"317","author":"Y Teng","year":"2025","unstructured":"Teng Y, Wang D, Yang Z, Wang R, Ning S, Zhang R, Yang H, Feng X, Liu J, Yang L. Bioorthogonal strategy-triggered In situ co-activation of aggregation-induced emission photosensitizers and chemotherapeutic prodrugs for boosting synergistic chemo-photodynamic-immunotherapy. Biomaterials. 2025;317:123092.","journal-title":"Biomaterials"},{"key":"4266_CR45","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.apsb.2022.05.011","volume":"13","author":"L Geng","year":"2023","unstructured":"Geng L, Lu T, Jing H, Zhou Y, Liang X, Li J, Li N. Iron-based and BRD4-downregulated strategy for amplified ferroptosis based on pH-sensitive\/NIR-II-boosted nano-matchbox. Acta Pharm Sinica B. 2023;13:863\u201378.","journal-title":"Acta Pharm Sinica B"},{"key":"4266_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bioactmat.2021.12.018","volume":"19","author":"H Peng","year":"2023","unstructured":"Peng H, Zhang X, Yang P, Zhao J, Zhang W, Feng N, Yang W, Tang J. Defect self-assembly of metal-organic framework triggers ferroptosis to overcome resistance. Bioactive Mater. 2023;19:1\u201311.","journal-title":"Bioactive Mater"},{"key":"4266_CR47","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12951-024-02517-1","volume":"22","author":"Z Lin","year":"2024","unstructured":"Lin Z, Xu G, Lu X, Liu S, Zou F, Ma X, Jiang J, Wang H, Song J. Chondrocyte-targeted exosome-mediated delivery of Nrf2 alleviates cartilaginous endplate degeneration by modulating mitochondrial fission. J Nanobiotechnol. 2024;22:281.","journal-title":"J Nanobiotechnol"},{"key":"4266_CR48","doi-asserted-by":"crossref","unstructured":"Sui SY, Zhang J, Xu SP, Wang Q, Wang PY, Pang D. Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells. Cell Death Dis. 2019;10:331.","DOI":"10.1038\/s41419-019-1564-7"},{"key":"4266_CR49","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12951-025-03307-z","volume":"23","author":"X Sha","year":"2025","unstructured":"Sha X, Wang C, Liu Y, Zhong N, Lu Y, Zhang Q, Lu S, He D, Jin Y, Tang Y. Multifunctional glycyrrhizic acid-loaded nanoplatform combining ferroptosis induction and HMGB1 blockade for enhanced tumor immunotherapy. J Nanobiotechnol. 2025;23:224.","journal-title":"J Nanobiotechnol"},{"key":"4266_CR50","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.neo.2021.11.002","volume":"23","author":"W Huang","year":"2021","unstructured":"Huang W, Chen K, Lu Y, Zhang D, Cheng Y, Li L, Huang W, He G, Liao H, Cai L. ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma. Neoplasia. 2021;23:1227\u201339.","journal-title":"Neoplasia"},{"key":"4266_CR51","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1182\/blood.2022019274","volume":"142","author":"A Schmitt","year":"2023","unstructured":"Schmitt A, Grimm M, Kreienkamp N, Junge H, Labisch J, Schuhknecht L, Sch\u00f6nfeld C, G\u00f6rsch E, Tibello A, Menck K. BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis. Blood. 2023;142:1143\u201355.","journal-title":"Blood"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04266-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04266-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04266-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:05:06Z","timestamp":1776326706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04266-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4266"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04266-9","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted according to protocols approved by the Institutional Animal Care and Use Committee of Fujian University of Traditional Chinese Medicine and adhered to American Association for Laboratory Animal Science guidelines. Animals were monitored for abnormal behaviors and humanely euthanized upon excessive health deterioration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"367"}}